https://www.selleckchem.com/products/VX-809.html
9%. However, after a median follow-up period of 50months (range 24 to 60months), no significant difference was apparent in the rates of TLF between any DES, although Orsiro still ranked as the best stent (58.6% probability to be the best). In addition, Orsiro had a lower rate of long-term definite stent thrombosis compared with Nobori/BioMatrix (OR 0.60; 95%CI 0.36 to 0.98; p=0.04) and lower rates of definite and probable stent thrombosis compared with Resolute (OR 0.66; 95%CI 0.45 to 0.99; p=0.04). No differences in cardiac mortality be
Gefällt mir
Kommentar
Teilen
